Latest
Period 10 Review: SEZL Surges 23% to Give Quality Growth Its Best Period as Piotroski Suffers Its Worst
Ten periods in, a flat market exposes pure factor divergence. Quality Growth leads at +4.50% as SEZL surges +23% for a second consecutive outsized gain and DAVE adds +9.65%. CANSLIM gains +2.90% as Micron rises +15.5% and the semiconductor theme extends. Piotroski records its worst period at −5.25% as GLOB collapses −18% and both Period 9 new entrants immediately implode.
2026
Period 9 Review: All Seven Screens Positive for the First Time as Quality Growth and Magic Formula Lead the Recovery
Nine periods in, the journal's first all-green sweep. Quality Growth leads at +3.39% on SEZL +14.4% and DAVE +11.1%. Magic Formula rebounds +2.95% as precious metals reverse their Period 8 collapse. CANSLIM holds positive at +0.72% as LRCX surges +20.9% and SMCI collapses −26.9%.
2026
Period 8 Review: All Seven Screens Red as Precious Metals Collapse and Broadcom Reverses
Second all-red period as precious metals collapse hits three screens at once. PAAS falls 16.5%, Broadcom slides 13.7%, FICO gives back recent gains. Value screens hold better than the NASDAQ's worst single period at −4.68%.
2026
Period 7 Review: Micron and SMCI Each Surge 30% in a Week, Sending CANSLIM to a New High
Five screens positive as semiconductor earnings dominate. MU and SMCI each surge ~30% in a week, driving CANSLIM to its best single-period return at +4.84% and a new cumulative high of +14.30%.
2026
Period 6 Review: Quality Rebounds to Its Best Period as FUTU Erases Lunch's Season Lead
Four screens positive after an all-red Period 5. Quality Growth posts its best single-period return at +2.98% on a FICO surge, while FUTU's −33% collapse wipes out Lunch's entire cumulative gain.
2026
Strategy 4 Has Great Taste — and a Guest List of 68
S4 has great bones — quality, growth, balance sheet discipline. It also has 68 stocks. Here is the one variable, at the right threshold, that turns it into a portfolio.
2026
Period 5 Review: The First All-Red Week, and CANSLIM Slips Behind the S&P 500
Seven days, zero screens positive, and the first time CANSLIM has trailed the S&P 500 cumulatively. A flat market week that exposed idiosyncratic risk across every strategy.
2026
Period 4 Review: Role Reversals, Heavy Turnover, and CANSLIM's Growing Lead
Eight days, six of seven screens positive, and the most dramatic single-period swing yet — Magic Formula bounces back while Piotroski stumbles. Four periods in.
2026
Period 3 Review: A Rising Market and the Point Where Every Screen Lags
Five more days, a market that keeps climbing, and the point at which every systematic screen now trails the S&P 500 cumulatively. Three periods in.
2026
Period 2 Review: Five Days, a Rebound, and the Signal in Stability
Five trading days, a market rebound, and what the screens reveal about strategy stability and short-term noise.
2026
Period 1 Review: How 7 Screens Fared compared to the Market
How 7 systematic stock screens performed across 43 days of a declining market. Retention rates, portfolio returns, and early lessons.
2026
The Stock Market as a Wealth Vehicle — and Why Most People Use It Wrong
Why equities are the most powerful wealth-building tool available to individual investors, what the risks actually are, and how systematic thinking changes your odds.